ASX Announcement 30 July 2026 Appendix 4C – June 2026 Quarterly Activities Report Highlights • Anne- Louise Arnett appointed Chief Executive Officer, effective 1 June 2026, bringing more than 25 years of medical technology commercialisation and operational leadership experience ...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 8 pages · English
Release
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- BCAL to Acquire Shares in Genetic Signatures
- BCAL Secures Funding for FY2027
- BCAL Develops New Blood Test for Breast Cancer Recurrence
- BCAL Launches Early Detection Cancer Platform
- BCAL Appoints Anne-Louise Arnett as Chief Executive Officer
Later from BCAL Diagnostics
- Bioshares Conference Investor Presentation
- Proposed issue of securities - BDX
- Notification regarding unquoted securities - BDX
- BCAL Secures Funding for FY2027 Update
- Change in Substantial Shareholder Notice for GSS
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics